Pneumococcal and Meningococcal Vaccines: Market Forecast

Introduction

Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that could reach $3.4 billion in infants and adults across the US and 5EU by 2019, leaving only marginal roles for its competitors. The commercial opportunity for MenACWY conjugate vaccines will largely remain restricted to the US, while a broad Men B vaccine could achieve blockbuster status.
Features and benefits

* Detailed sales forecasts for the currently available brands and late-stage pipeline vaccines in the US and 5EU.* Forecast of key marketed vaccines and late stage pipeline products.
Highlights

Datamonitor anticipates the launch of Pfizer’s Prevnar 13 for adults in 2011 and expects the vaccine to quickly replace Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.4 billion in 2019 across the US and five major EU marketsSales expectations for conjugate MenACWY vaccines are limited in the seven major markets. While the US are unlikely to recommend routine MenACWY vaccination of infants, MenACWY vaccines will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs. Best growth opportunities lie in a MenB vaccine.Pneumo- and meningococcal vaccines continue to offer great commercial opportunities, due to changing disease epidemiology and the need for broader age indications. Novartis’ 4CMenB is the most promising pipeline vaccine and expected to reach blockbuster status with possible sales of almost $3 billion in the US and the five major European markets.
Your key questions answered

* Obtain full country and product-specific forecasts of currently marketed and pipeline pneumo- and meningococcal vaccines from 2010 to 2019.* Identify the market dynamics of pneumo- and meningococcal vaccines and the commercial potential of late stage pipeline.

[Studien Infos ausblenden]

#NV
[Inhaltsverzeichnis ausblenden]